Canterbury Christ Church University's repository of research outputs

http://create.canterbury.ac.uk

Please cite this publication as follows:


Link to official URL (if available):

http://dx.doi.org/10.1136/bjsports-2017-097747

This version is made available in accordance with publishers' policies. All material made available by CReaTE is protected by intellectual property law, including copyright law. Any use made of the contents should comply with the relevant law.

Contact: create.library@canterbury.ac.uk
“Caution, this treatment is a placebo. It might work, but it might not”: Why emerging mechanistic evidence for placebo effects does not legitimize complementary and alternative medicines in sport.

Chris Beedie¹, Greg Whyte², Andrew M. Lane³, Emma Cohen⁴, John Raglin⁵, Phil Hurst¹, Damian Coleman¹ and Abby Foad¹

¹School of Human & Life Sciences, Canterbury Christ Church University, UK
²Research Institute for Sport & Exercise Science, Liverpool John Moores University, UK
³Institute of Sport, University of Wolverhampton, UK
⁴Institute of Cognitive & Evolutionary Anthropology, University of Oxford, UK.
⁵School of Public Health, Indiana University, USA

Corresponding author.

Dr Chris Beedie,
School of Human & Life Sciences
Canterbury Christ Church University
Kent, CT1 1QU.
UK
Email chris.beedie@canterbury.ac.uk
Complementary and alternative medicines (CAM) are treatments for which either evidence is lacking, or for which evidence suggests no effect over a placebo treatment. When a non-evidence-based treatment is used alongside conventional medicine, it is considered "complementary". When a non evidence-based treatment is used instead of conventional medicine, it is considered "alternative". Many forms of CAM have origins and/or a history of use beyond evidence-based medicine. Further, many CAM treatments are based on principles and/or evidence that are not recognised by the majority of independent scientists. When a person uses CAM and experiences an improvement in symptoms, this may be due to the placebo effect (1).

CAM is widely used in sport, often by elite athletes. One example is Michael Phelps’ use of ‘cupping’ during the 2016 Olympics. Evidence for the effectiveness of CAM in sport has been reported in some work, but more studies have reported CAM outcomes as no better than placebo. The link between CAM and the placebo effect has been made explicit by health agencies (1) and scientists. (2) As a consequence, where credible causal mechanisms for apparent therapeutic effects are absent, placebo effects are often assumed.

The placebo effect was historically considered a non-specific phenomenon, but recent studies indicate numerous discrete placebo effects operating via dopamine,(3) opioid,(4) and cannabinoid(5) neurotransmission. For example, placebo analgesia following preconditioning with morphine is blocked by the antagonist naloxone, but analgesia conditioned using a non-opioid drug was naloxone insensitive. Likewise, the cannabinoid receptor antagonist rimonabant had no effect on opioid-induced placebo analgesia following preconditioning with morphine, but antagonised placebo analgesia following preconditioning with the nonopioid NSAID, ketorolac.

Such connections between brain physiology and mechanistic evidence is being used as an argument for CAM. We have been researching the placebo effect in sport for some time (14 years in the case of the first author). Whilst it is not unusual to be invited to speak at scientific conferences or to media on one’s area of expertise, we now receive as many invitations to speak on the issue of CAM, and an equal volume of traffic from proponents
and/or practitioners of CAM, at times congratulating us for ‘legitimizing’ their product or treatment.

We strongly contest this position, and propose five challenges to the idea that placebo mechanisms legitimise the use of CAM by clinicians in sports medicine/sports physiotherapy:

1. **Variability:** Placebo responding is variable, both between and within athletes.\(^6\) Furthermore, most research papers report acute placebo effects, and little is known about their stability over time.

2. **Negative placebo effects:** The nocebo effect, a negative response related to negative expectations, is well documented.\(^6\) Rather than assuming that a CAM treatment will either result in a positive effect or no effect, practitioners must consider the possibility that administration of a placebo treatment can exert a negative effect.

3. **Failure to adopt a more effective treatment.** Athletes are often eager to accept at face value treatments that might expedite their return to play.\(^7\) Consequently, patients of practitioners who administer CAM may be denied or choose to forego potentially more effective evidence-based treatments.\(^8\) In sport, this might range from an athlete not eating sufficient fresh fruit because she is receiving sufficient vitamin C through supplements, to choosing CAM as opposed to conventional medicine to treat injury or illness.

4. **Ethics of deception:** In light of the challenges of points 1 and 2, it is arguably unethical to knowingly advocate CAM while also assuming the likely mechanism of effect is the placebo. We acknowledge emerging evidence that open label administration of placebos can be effective. However, even in such cases, the administration of placebos may ultimately be counterproductive. There are serious ethical challenges around deception, risk and harm to patients.

5. **Identification of “headroom” mechanisms:** The capacity to respond to a placebo is evidence of headroom or reserve capacity.\(^6\) Headroom is likely amenable to legitimate treatments, both physiological and psychological. Practitioners should strive to identify and capitalize on headroom through legitimate, ethical, controllable and stable treatments (e.g., optimal nutrition, systematic recovery, and psychological skills training).
CAM can be effective, but can also be ineffective or even harmful. Evidence is vague in both respects, but practitioners and athletes using CAM do not always recognize this. We acknowledge the distinction between lack of evidence for an effect, and evidence for the lack of an effect. In relation to the former, sports medicine researchers should seek to use robust, reliable and, where necessary, innovative methods to establish the efficacy and mechanisms of CAM treatments. In relation to the latter, sports medicine practitioners should regard non-evidence based treatments with caution, and resist the temptation to rely on non-specific effects as a basis for prescription. If a practitioner seeks to use a treatment in order to capitalize on the placebo component of that treatment, they should do so methodically.(9)

We acknowledge that in sports medicine the outcome is often more important than the mechanism. Scientific research on placebo mechanisms has yielded fascinating insights suggesting the potential efficacy and mechanisms of belief-based treatments. We anticipate that when applied systematically, such research findings enable sports medicine practitioners to deliver all treatments – CAM and conventional - more effectively. But such use of the placebo component of a treatment does not legitimise CAM per se; whilst it might be going too far to suggest that many CAM treatments should be labeled with the statement “Caution: This treatment is a placebo, it may work, but it may not, it might even be counter-productive”, we argue this is most certainly the reality that practitioners should keep in mind.

References